Improved Prevention of Stroke in Primary Care in Stockholm, Sweden (Förbättrad Prevention av Stroke)
Stroke is a devastating disease. The acute mortality in Sweden is 20 % and 25 % of all patients relapse. Secondary prevention is proven efficient but observational studies have shown that a number of patients are lost to follow up and do not receive recommended prevention. The aim of the study is to 1) describe, by analyzing register data, the detection rate of patients with hospital diagnosis of stroke, TIA, and atrial fibrillation in the primary care center where they are listed. The analysis is done by sex, age, and socioeconomic status. Furthermore, rate of dispensed prescriptions of secondary preventive drugs are analysed for the identified population. 2) in a randomized controlled study evaluate if collegial feed back and targeted information of secondary prevention to the intervention group can improve the detection rate and the medication of the patients listed at the participating primary care centers.
Behavioral: structured collegial feed back
|Study Design:||Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Prevention
|Official Title:||An Interventional Study of How Collegial Feed Back to Primary Care Physicians on Detection of Diagnosis and Dispensation of Prescribed Secondary Preventive Drugs Affect Stroke Prevention.|
- percentage of identified patients with stroke/TIA in primary care and analysis of dispensed prescriptions in each group [ Time Frame: Outcome meassures will be followed during two years ] [ Designated as safety issue: No ]percentage of patients identified with hospital discharge diagnosis of stroke/TIA in primary care diagnosis register. Analysis of changes in outcome before intervention and after. the intervention will take place during one year and collection of data before start of intervention and one year after ended intervention will be performed
- dispensed prescriptions of secondary preventives drugs in patients with stroke/TIA [ Time Frame: baseline 2010 and 2012, followed for one year after intervention ] [ Designated as safety issue: No ]dispensed prescriptions of recommended secondary preventive drugs in patients detected and not detected at each primary care center
|Study Start Date:||October 2013|
|Estimated Study Completion Date:||October 2015|
|Estimated Primary Completion Date:||October 2015 (Final data collection date for primary outcome measure)|
Experimental: structured collegial feed back
Structured feed back and information about stroke to the primary care center, to physicians and head of the center
Behavioral: structured collegial feed back
Collegial feed back to primary care physicians at randomized primary care centers
No Intervention: Control group
No structured feed back on stroke prevention. Ordinary educational activities only.
All primary care centers in Stockholm County (approximately 200) are randomised to control or intervention (receiving structured feed back on detection rate of stroke/transient ischemic attacks in comparison to hospital discharge registry data. The randomisation is done group wise based on training areas. A data set is presented by different means; 1) in written reports, directly to the head of each primary care center in the intervention group 2)in oral presentation on training sessions for the physicians in each training ares. Measures of detection rates of diagnosis and dispensed prescriptions of secondary preventive drugs are made before start of the project and after one year. The control group, ie the primary care centers not receiving feed back, are measured in the same way and thus provide a control group. The hypothesis being that with visibility of the problem, it is easier to improve care wich is what all health providers aim to do.
Outcome measures is percentage of patients with stroke (ICD code I60, I 61, I63, I64) and transitory ischemic attacks(G45) who are dispensed prescribed secondary preventive medication and death.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01942031
|Karolinska Institutet Stroke Research Network at Södersjukhuset|
|Principal Investigator:||Mia von Euler, MD, PhD||Karolinska Institutet|